Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:DDX3X-KRT13

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: DDX3X-KRT13
	FusionPDB ID: 21984
	FusionGDB2.0 ID: 21984
		Hgene	Tgene
	Gene symbol	DDX3X	KRT13
	Gene ID	1654	3860
	Gene name	DEAD-box helicase 3 X-linked	keratin 13
	Synonyms	CAP-Rf\|DBX\|DDX14\|DDX3\|HLP2\|MRX102	CK13\|K13\|WSN2
	Cytomap	Xp11.4	17q21.2
	Type of gene	protein-coding	protein-coding
	Description	ATP-dependent RNA helicase DDX3XDEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linkedDEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linkedDEAD box protein 3, X-chromosomalDEAD box, X isoformDEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3DEAD/H box-3helicase-	keratin, type I cytoskeletal 13CK-13cytokeratin 13keratin 13, type I
	Modification date	20200329	20200313
	UniProtAcc	O00571 Main function of 5'-partner protein: FUNCTION: Multifunctional ATP-dependent RNA helicase (PubMed:17357160, PubMed:21589879, PubMed:31575075). The ATPase activity can be stimulated by various ribo-and deoxynucleic acids indicative for a relaxed substrate specificity (PubMed:29222110). In vitro can unwind partially double-stranded DNA with a preference for 5'-single-stranded DNA overhangs (PubMed:17357160, PubMed:21589879). Binds RNA G-quadruplex (rG4s) structures, including those located in the 5'-UTR of NRAS mRNA (PubMed:30256975). Involved in many cellular processes, which do not necessarily require its ATPase/helicase catalytic activities (Probable). Involved in transcription regulation (PubMed:16818630, PubMed:18264132). Positively regulates CDKN1A/WAF1/CIP1 transcription in an SP1-dependent manner, hence inhibits cell growth. This function requires its ATPase, but not helicase activity (PubMed:16818630, PubMed:18264132). CDKN1A up-regulation may be cell-type specific (PubMed:18264132). Binds CDH1/E-cadherin promoter and represses its transcription (PubMed:18264132). Potentiates HNF4A-mediated MTTP transcriptional activation; this function requires ATPase, but not helicase activity. Facilitates HNF4A acetylation, possibly catalyzed by CREBBP/EP300, thereby increasing the DNA-binding affinity of HNF4 to its response element. In addition, disrupts the interaction between HNF4 and SHP that forms inactive heterodimers and enhances the formation of active HNF4 homodimers. By promoting HNF4A-induced MTTP expression, may play a role in lipid homeostasis (PubMed:28128295). May positively regulate TP53 transcription (PubMed:28842590). Associates with mRNPs, predominantly with spliced mRNAs carrying an exon junction complex (EJC) (PubMed:17095540, PubMed:18596238). Involved in the regulation of translation initiation (PubMed:18628297, PubMed:17667941, PubMed:22872150). Not involved in the general process of translation, but promotes efficient translation of selected complex mRNAs, containing highly structured 5'-untranslated regions (UTR) (PubMed:20837705, PubMed:22872150). This function depends on helicase activity (PubMed:20837705, PubMed:22872150). Might facilitate translation by resolving secondary structures of 5'-UTRs during ribosome scanning (PubMed:20837705). Alternatively, may act prior to 43S ribosomal scanning and promote 43S pre-initiation complex entry to mRNAs exhibiting specific RNA motifs, by performing local remodeling of transcript structures located close to the cap moiety (PubMed:22872150). Independently of its ATPase activity, promotes the assembly of functional 80S ribosomes and disassembles from ribosomes prior to the translation elongation process (PubMed:22323517). Positively regulates the translation of cyclin E1/CCNE1 mRNA and consequently promotes G1/S-phase transition during the cell cycle (PubMed:20837705). May activate TP53 translation (PubMed:28842590). Required for endoplasmic reticulum stress-induced ATF4 mRNA translation (PubMed:29062139). Independently of its ATPase/helicase activity, enhances IRES-mediated translation; this activity requires interaction with EIF4E (PubMed:17667941, PubMed:22323517). Independently of its ATPase/helicase activity, has also been shown specifically repress cap-dependent translation, possibly by acting on translation initiation factor EIF4E (PubMed:17667941). Involved in innate immunity, acting as a viral RNA sensor. Binds viral RNAs and promotes the production of type I interferon (IFN-alpha and IFN-beta) (PubMed:31575075, PubMed:20127681, PubMed:21170385). Potentiate MAVS/DDX58-mediated induction of IFNB in early stages of infection (PubMed:20127681, PubMed:21170385). Enhances IFNB1 expression via IRF3/IRF7 pathway and participates in NFKB activation in the presence of MAVS and TBK1 (PubMed:18583960, PubMed:18636090, PubMed:21170385, PubMed:27980081, PubMed:19913487). Involved in TBK1 and IKBKE-dependent IRF3 activation leading to IFNB induction, acts as a scaffolding adapter that links IKBKE and IRF3 and coordinates their activation (PubMed:23478265). Involved in the TLR7/TLR8 signaling pathway leading to type I interferon induction, including IFNA4 production. In this context, acts as an upstream regulator of IRF7 activation by MAP3K14/NIK and CHUK/IKKA. Stimulates CHUK autophosphorylation and activation following physiological activation of the TLR7 and TLR8 pathways, leading to MAP3K14/CHUK-mediated activatory phosphorylation of IRF7 (PubMed:30341167). Also stimulates MAP3K14/CHUK-dependent NF-kappa-B signaling (PubMed:30341167). Negatively regulates TNF-induced IL6 and IL8 expression, via the NF-kappa-B pathway. May act by interacting with RELA/p65 and trapping it in the cytoplasm (PubMed:27736973). May also bind IFNB promoter; the function is independent of IRF3 (PubMed:18583960). Involved in both stress and inflammatory responses (By similarity). Independently of its ATPase/helicase activity, required for efficient stress granule assembly through its interaction with EIF4E, hence promotes survival in stressed cells (PubMed:21883093). Independently of its helicase activity, regulates NLRP3 inflammasome assembly through interaction with NLRP3 and hence promotes cell death by pyroptosis during inflammation. This function is independent of helicase activity (By similarity). Therefore DDX3X availability may be used to interpret stress signals and choose between pro-survival stress granules and pyroptotic NLRP3 inflammasomes and serve as a live-or-die checkpoint in stressed cells (By similarity). In association with GSK3A/B, negatively regulates extrinsic apoptotic signaling pathway via death domain receptors, including TNFRSF10B, slowing down the rate of CASP3 activation following death receptor stimulation (PubMed:18846110). Cleavage by caspases may inactivate DDX3X and relieve the inhibition (PubMed:18846110). Independently of its ATPase/helicase activity, allosteric activator of CSNK1E. Stimulates CSNK1E-mediated phosphorylation of DVL2, thereby involved in the positive regulation of Wnt/beta-catenin signaling pathway. Also activates CSNK1A1 and CSNK1D in vitro, but it is uncertain if these targets are physiologically relevant (PubMed:23413191, PubMed:29222110). ATPase and casein kinase-activating functions are mutually exclusive (PubMed:29222110). May be involved in mitotic chromosome segregation (PubMed:21730191). {ECO:0000250\|UniProtKB:Q62167, ECO:0000269\|PubMed:16818630, ECO:0000269\|PubMed:17095540, ECO:0000269\|PubMed:17357160, ECO:0000269\|PubMed:17667941, ECO:0000269\|PubMed:18264132, ECO:0000269\|PubMed:18583960, ECO:0000269\|PubMed:18596238, ECO:0000269\|PubMed:18628297, ECO:0000269\|PubMed:18636090, ECO:0000269\|PubMed:18846110, ECO:0000269\|PubMed:19913487, ECO:0000269\|PubMed:20127681, ECO:0000269\|PubMed:20837705, ECO:0000269\|PubMed:21170385, ECO:0000269\|PubMed:21589879, ECO:0000269\|PubMed:21730191, ECO:0000269\|PubMed:21883093, ECO:0000269\|PubMed:22323517, ECO:0000269\|PubMed:22872150, ECO:0000269\|PubMed:23413191, ECO:0000269\|PubMed:23478265, ECO:0000269\|PubMed:27736973, ECO:0000269\|PubMed:27980081, ECO:0000269\|PubMed:28128295, ECO:0000269\|PubMed:28842590, ECO:0000269\|PubMed:29062139, ECO:0000269\|PubMed:29222110, ECO:0000269\|PubMed:30256975, ECO:0000269\|PubMed:30341167, ECO:0000269\|PubMed:31575075, ECO:0000305}.; FUNCTION: (Microbial infection) Facilitates hepatitis C virus (HCV) replication (PubMed:29899501). During infection, HCV core protein inhibits the interaction between MAVS and DDX3X and therefore impairs MAVS-dependent INFB induction and might recruit DDX3X to HCV replication complex (PubMed:21170385). {ECO:0000269\|PubMed:21170385, ECO:0000269\|PubMed:29899501}.; FUNCTION: (Microbial infection) Facilitates HIV-1 replication (PubMed:15507209, PubMed:18583960, PubMed:21589879, PubMed:22872150, PubMed:29899501). Acts as a cofactor for XPO1-mediated nuclear export of HIV-1 Rev RNAs (PubMed:15507209, PubMed:18583960, PubMed:29899501). This function is strongly stimulated in the presence of TBK1 and requires DDX3X ATPase activity (PubMed:18583960). {ECO:0000269\|PubMed:15507209, ECO:0000269\|PubMed:18583960, ECO:0000269\|PubMed:21589879, ECO:0000269\|PubMed:22872150, ECO:0000269\|PubMed:29899501}.; FUNCTION: (Microbial infection) Facilitates Zika virus (ZIKV) replication. {ECO:0000269\|PubMed:29899501}.; FUNCTION: (Microbial infection) Facilitates Dengue virus (DENV) replication. {ECO:0000269\|PubMed:29899501}.; FUNCTION: (Microbial infection) Facilitates Venezuelan equine encephalitis virus (VEEV) replication. {ECO:0000269\|PubMed:27105836}.	P13646 Main function of 5'-partner protein:
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000478993, ENST00000399959, ENST00000441189, ENST00000457138, ENST00000542215,	ENST00000246635, ENST00000336861, ENST00000587544, ENST00000587118,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	8 X 9 X 6=432	19 X 33 X 6=3762
	# samples	8	24
	** MAII score	log2(8/432*10)=-2.43295940727611 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(24/3762*10)=-3.97039353791468 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: DDX3X [Title/Abstract] AND KRT13 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: DDX3X [Title/Abstract] AND KRT13 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	DDX3X(41206905)-KRT13(39661579), # samples:1 DDX3X(41206907)-KRT13(39661625), # samples:1
Anticipated loss of major functional domain due to fusion event.	DDX3X-KRT13 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. DDX3X-KRT13 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. DDX3X-KRT13 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. DDX3X-KRT13 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. DDX3X-KRT13 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. DDX3X-KRT13 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. DDX3X-KRT13 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	DDX3X	GO:0009615	response to virus	18636090
Hgene	DDX3X	GO:0010501	RNA secondary structure unwinding	22872150
Hgene	DDX3X	GO:0010628	positive regulation of gene expression	10074132
Hgene	DDX3X	GO:0030308	negative regulation of cell growth	16818630
Hgene	DDX3X	GO:0031333	negative regulation of protein complex assembly	17667941
Hgene	DDX3X	GO:0031954	positive regulation of protein autophosphorylation	30341167
Hgene	DDX3X	GO:0032727	positive regulation of interferon-alpha production	30341167
Hgene	DDX3X	GO:0032728	positive regulation of interferon-beta production	27980081
Hgene	DDX3X	GO:0034063	stress granule assembly	21883093
Hgene	DDX3X	GO:0034157	positive regulation of toll-like receptor 7 signaling pathway	30341167
Hgene	DDX3X	GO:0034161	positive regulation of toll-like receptor 8 signaling pathway	30341167
Hgene	DDX3X	GO:0035556	intracellular signal transduction	18636090
Hgene	DDX3X	GO:0045727	positive regulation of translation	18596238\|22872150
Hgene	DDX3X	GO:0045944	positive regulation of transcription by RNA polymerase II	16818630\|18636090\|28128295
Hgene	DDX3X	GO:0071243	cellular response to arsenic-containing substance	21883093
Hgene	DDX3X	GO:0071470	cellular response to osmotic stress	21883093
Hgene	DDX3X	GO:0071902	positive regulation of protein serine/threonine kinase activity	23413191
Hgene	DDX3X	GO:1902523	positive regulation of protein K63-linked ubiquitination	27980081
Tgene	KRT13	GO:0007010	cytoskeleton organization	21371075

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chrX:41206905/chr17:39661579)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across DDX3X (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across KRT13 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000399959	DDX3X	chrX	41206905	+	ENST00000336861	KRT13	chr17	39661579	-	6724	5321	855	2846	663
ENST00000399959	DDX3X	chrX	41206905	+	ENST00000246635	KRT13	chr17	39661579	-	6750	5321	855	2846	663
ENST00000399959	DDX3X	chrX	41206905	+	ENST00000587544	KRT13	chr17	39661579	-	6491	5321	855	2846	663
ENST00000441189	DDX3X	chrX	41206905	+	ENST00000336861	KRT13	chr17	39661579	-	2441	1038	91	513	140
ENST00000441189	DDX3X	chrX	41206905	+	ENST00000246635	KRT13	chr17	39661579	-	2467	1038	91	513	140
ENST00000441189	DDX3X	chrX	41206905	+	ENST00000587544	KRT13	chr17	39661579	-	2208	1038	91	513	140
ENST00000399959	DDX3X	chrX	41206907	+	ENST00000336861	KRT13	chr17	39661625	-	6768	5319	855	2828	657
ENST00000399959	DDX3X	chrX	41206907	+	ENST00000246635	KRT13	chr17	39661625	-	6794	5319	855	2828	657
ENST00000399959	DDX3X	chrX	41206907	+	ENST00000587544	KRT13	chr17	39661625	-	6535	5319	855	2828	657
ENST00000441189	DDX3X	chrX	41206907	+	ENST00000336861	KRT13	chr17	39661625	-	2485	1036	1901	2392	163
ENST00000441189	DDX3X	chrX	41206907	+	ENST00000246635	KRT13	chr17	39661625	-	2511	1036	1927	2418	163
ENST00000441189	DDX3X	chrX	41206907	+	ENST00000587544	KRT13	chr17	39661625	-	2252	1036	1668	2159	163

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000399959	ENST00000336861	DDX3X	chrX	41206905	+	KRT13	chr17	39661579	-	0.000884035	0.999116
ENST00000399959	ENST00000246635	DDX3X	chrX	41206905	+	KRT13	chr17	39661579	-	0.000922997	0.99907696
ENST00000399959	ENST00000587544	DDX3X	chrX	41206905	+	KRT13	chr17	39661579	-	0.00091004	0.99908996
ENST00000441189	ENST00000336861	DDX3X	chrX	41206905	+	KRT13	chr17	39661579	-	0.009790508	0.99020946
ENST00000441189	ENST00000246635	DDX3X	chrX	41206905	+	KRT13	chr17	39661579	-	0.015351403	0.9846485
ENST00000441189	ENST00000587544	DDX3X	chrX	41206905	+	KRT13	chr17	39661579	-	0.008597597	0.99140245
ENST00000399959	ENST00000336861	DDX3X	chrX	41206907	+	KRT13	chr17	39661625	-	0.000933795	0.9990662
ENST00000399959	ENST00000246635	DDX3X	chrX	41206907	+	KRT13	chr17	39661625	-	0.000976246	0.9990238
ENST00000399959	ENST00000587544	DDX3X	chrX	41206907	+	KRT13	chr17	39661625	-	0.000971992	0.99902797
ENST00000441189	ENST00000336861	DDX3X	chrX	41206907	+	KRT13	chr17	39661625	-	0.00835389	0.9916461
ENST00000441189	ENST00000246635	DDX3X	chrX	41206907	+	KRT13	chr17	39661625	-	0.009178149	0.99082184
ENST00000441189	ENST00000587544	DDX3X	chrX	41206907	+	KRT13	chr17	39661625	-	0.007682975	0.9923171

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for DDX3X-KRT13

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene

Hchr

Hbp

Tgene

Tchr

Tbp

Length(fusion protein)

BP in fusion protein

Peptide

Top

Potential FusionNeoAntigen Information of DDX3X-KRT13 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA I

FusionNeoAntigen peptide

Binding score

Immunogenic score

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Potential FusionNeoAntigen Information of DDX3X-KRT13 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of DDX3X-KRT13

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of DDX3X-KRT13

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele

PDB ID

File name

BPseq

Docking score

Glide score

Top

Vaccine Design for the FusionNeoAntigens of DDX3X-KRT13

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide sequence

FusionNeoAntigen RNA sequence

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of DDX3X-KRT13

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type

Fusion gene

Hchr

Hbp

Henst

Tchr

Tbp

Tenst

Sample

Top

Potential target of CAR-T therapy development for DDX3X-KRT13

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to DDX3X-KRT13

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to DDX3X-KRT13

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)